As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, discusses the benefits ...
Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a ...
This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis. Objectives: To estimate the ...
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results